12.07.2015 Views

7817 Annual Report 2009.qxd - Shire

7817 Annual Report 2009.qxd - Shire

7817 Annual Report 2009.qxd - Shire

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

34 <strong>Shire</strong> plc <strong>Annual</strong> <strong>Report</strong> and Accounts 2009Directors’ reportThe Directors present their report on the affairs of the Group together with the audited consolidated financial statements for the year endedDecember 31, 2009.Principal activity<strong>Shire</strong> plc (the ‘Company’) and its subsidiaries (collectively referred to as the ‘Group’ or ‘<strong>Shire</strong>’) is a leading specialty biopharmaceutical company thatfocuses on meeting the needs of the specialist physician.<strong>Shire</strong> focuses its business on attention deficit hyperactivity disorder, human genetic therapies and gastrointestinal therapeutic areas.The subsidiaries and equity-method investees principally affecting the profits and/or net assets of <strong>Shire</strong> in the year are listed in Note 34 to theconsolidated financial statements, including their country of incorporation.Business review<strong>Shire</strong> is required to set out in this report a fair review of the business of the Group during the financial year to December 31, 2009, the position ofthe Group at the end of that financial year, and a description of the principal risks and uncertainties facing the Group. The information that fulfils therequirements of the Business Review can be found in the Chairman’s review on pages 2 and 3, the Chief Executive Officer’s review on pages 4 to 7,the Financial review on pages 8 to 31 and the corporate governance statement on pages 39 to 44 which are incorporated in this report by reference.The Financial review and Note 22 to the consolidated financial statements also provide a description of the principal risks and uncertainties facing theGroup as well as risk management objectives and policies.There were no significant events subsequent to the balance sheet date.There are no material differences between market and balance sheet values of land, the accounting policy of which is set out in Note 2 to theconsolidated financial statements.Results and dividendsThe income from continuing operations before income taxes, and equity in (losses)/earnings of equity-method investees for the year to December31, 2009 was $643.0 million (2008: $265.6 million). The net assets of <strong>Shire</strong> at December 31, 2009 were $1,912.5 million (December 31, 2008:$1,327.5 million).In respect of the six months to December 31, 2009 the Board resolved to pay a second interim dividend of 9.250 US cents (2008: 7.761 US cents)per Ordinary Share. Together with the first interim payment of 2.147 US cents (2008: 2.147 US cents) per Ordinary Share, this represents totaldividends for 2009 of 11.397 US cents (2008: 9.908 US cents) per Ordinary Share.ExcellerateHRO (Guernsey) Limited, trustee of the <strong>Shire</strong> Employee Benefit Trust (the ‘Trust’), has waived its entitlement to any dividends, whichbecome due and payable in respect of shares or other securities, which are registered in the name of the trustee or its nominee(s), from time to time,except the right to receive 0.0001 pence per share.Liquidity, cash flow and going concernThe Group’s business activities, together with the factors likely to affect its future development, performance and position are set out in the Chairman’sreview, Chief Executive Officer’s review and Financial review on pages 2 to 31. The financial position of the Group, its cash flows, liquidity position andborrowing facilities are described in the Liquidity and capital resources section of the Financial review. The Financial review also includes information inrespect of the Group’s objectives, policies and processes for managing capital; its financial risk management objectives; details of its hedging activity;and its exposures to credit risk and liquidity risk. Details of the Group’s financial instruments are disclosed in Note 22 to the consolidated financialstatements.<strong>Shire</strong>’s balance sheet includes $498.9 million of cash and cash equivalents at December 31, 2009. <strong>Shire</strong> has no debt maturing in the next two yearsand substantially all of <strong>Shire</strong>’s debt relates to its $1,100 million 2.75% convertible bond which matures in 2014, although these bonds include a putoption which could require repayment of the bonds in 2012. In addition, <strong>Shire</strong> has a committed facility until 2012 of $1,200 million, which is currentlyundrawn. The current financial situation affecting the banking system and financial markets, together with the current uncertainty in global economicconditions, has resulted in tighter credit markets and a lower level of liquidity in many financial markets. As a result, the Group may not be able toaccess new equity or debt finance at the same level or cost as it has done previously.The Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future.Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.Corporate governanceThe Directors are committed to business integrity and professionalism and as an essential part of this commitment the Board supports high standardsof corporate governance. Details relating to corporate governance and <strong>Shire</strong>’s compliance with the Combined Code on Corporate Governance publishedby the UK Financial <strong>Report</strong>ing Council in June 2008 for the 2009 financial year are given on pages 39 to 44 and in the remuneration policy contained inthe Directors’ remuneration report which is detailed on pages 48 to 61. The Directors’ remuneration report contains details of Directors’ service contracts,whilst the Corporate governance statement includes further details on the appointment of Directors and the responsibilities of the Board.Share capitalAt December 31, 2009 the Company’s issued share capital comprised 561,477,011 Ordinary Shares and 2 Subscriber Ordinary Shares. Further detailsof the authorized and called up share capital of the Company as at December 31, 2009 and the changes during the year are set out in Note 25 to theconsolidated financial statements.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!